Evaluation of duration of antibiotic therapy across hospitals in Scotland including the impact of COVID-19 pandemic : a segmented interrupted time series analysis
BACKGROUND: Little is known about the duration of antibiotic use in hospital settings. We evaluated the duration of hospital antibiotic therapy for four commonly prescribed antibiotics (amoxicillin, co-amoxiclav, doxycycline, and flucloxacillin) including the assessment of COVID-19 impact.
METHODS: A repeated, cross-sectional study using the Hospital Electronic Prescribing and Medicines Administration system (January/2019-March/2022). Monthly median duration of therapy/duration categories was calculated, stratified by routes of administration, age, and sex. The impact of COVID-19 was assessed using segmented time-series analysis.
RESULTS: There were significant variations in the median duration of therapy across routes of administration (P < 0.05), with the highest value among those antibiotic courses composed of both oral and IV antibiotics ('Both' group). Significantly higher proportions of prescriptions within the 'Both' group had a duration of >7 days compared to oral or IV. The duration of therapy differed significantly by age. Some small statistically significant changes in the level/trends of duration of therapy were observed in the post-COVID-19 period.
CONCLUSIONS: No evidence for prolonged duration of therapy were observed, even during COVID-19 pandemic. The duration of IV therapy was relatively short, suggesting timely clinical review and consideration of IV to oral switch. Longer duration of therapy was observed among older patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Expert review of anti-infective therapy - 21(2023), 4 vom: 17. Apr., Seite 455-475 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kurdi, Amanj [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 27.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14787210.2023.2181789 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35309787X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35309787X | ||
| 003 | DE-627 | ||
| 005 | 20231226055226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14787210.2023.2181789 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM35309787X | ||
| 035 | |a (NLM)36803370 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kurdi, Amanj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of duration of antibiotic therapy across hospitals in Scotland including the impact of COVID-19 pandemic |b a segmented interrupted time series analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 27.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Little is known about the duration of antibiotic use in hospital settings. We evaluated the duration of hospital antibiotic therapy for four commonly prescribed antibiotics (amoxicillin, co-amoxiclav, doxycycline, and flucloxacillin) including the assessment of COVID-19 impact | ||
| 520 | |a METHODS: A repeated, cross-sectional study using the Hospital Electronic Prescribing and Medicines Administration system (January/2019-March/2022). Monthly median duration of therapy/duration categories was calculated, stratified by routes of administration, age, and sex. The impact of COVID-19 was assessed using segmented time-series analysis | ||
| 520 | |a RESULTS: There were significant variations in the median duration of therapy across routes of administration (P < 0.05), with the highest value among those antibiotic courses composed of both oral and IV antibiotics ('Both' group). Significantly higher proportions of prescriptions within the 'Both' group had a duration of >7 days compared to oral or IV. The duration of therapy differed significantly by age. Some small statistically significant changes in the level/trends of duration of therapy were observed in the post-COVID-19 period | ||
| 520 | |a CONCLUSIONS: No evidence for prolonged duration of therapy were observed, even during COVID-19 pandemic. The duration of IV therapy was relatively short, suggesting timely clinical review and consideration of IV to oral switch. Longer duration of therapy was observed among older patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibiotics | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a duration of therapy | |
| 650 | 4 | |a hospital electronic prescribing and medicines administration system | |
| 650 | 4 | |a segmented time-series analysis | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Platt, Niketa |e verfasserin |4 aut | |
| 700 | 1 | |a Morrison, Aidan |e verfasserin |4 aut | |
| 700 | 1 | |a Proud, Euan |e verfasserin |4 aut | |
| 700 | 1 | |a Gronkowski, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Seaton, R Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Malcolm, William |e verfasserin |4 aut | |
| 700 | 1 | |a Bennie, Marion |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anti-infective therapy |d 2003 |g 21(2023), 4 vom: 17. Apr., Seite 455-475 |w (DE-627)NLM151540101 |x 1744-8336 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:4 |g day:17 |g month:04 |g pages:455-475 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14787210.2023.2181789 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 4 |b 17 |c 04 |h 455-475 | ||